Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now !

Actinic Keratosis Market

DelveInsight’s ‘Actinic Keratosis (AK)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Actinic Keratosis (AK) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Actinic Keratosis symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Actinic Keratosis (AK) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Actinic Keratosis (AK) Disease Understanding and Treatment Algorithm

Actinic Keratosis (AK) Overview

Actinic Keratosis (AK), also referred to as senile keratosis or solar keratosis, are benign intra-epithelial neoplasms and represent one of the most common skin disorders evaluated by dermatologists. Often associated with chronic sun exposure, individuals with Actinic Keratosis may present with irregular, red, scaly papules or plaques on sun-exposed regions of the body. If left untreated, Actinic Keratosis have the potential to evolve into invasive squamous cell carcinoma, which underscores the importance of early detection and development of a treatment plan.

 

Actinic Keratosis lesions and sun related skin cancer and is known by many as ‘field cancerization’. In Actinic Keratosis, field cancerization occurs as a result of neoplastic changes induced by ultraviolet (UV) light across the whole sun exposed field of the skin. Various Actinic Keratosis stages can coexist within the cancerized field, which have become better characterized with the development of new imaging tools, such as confocal microscopy. These stages include individual UV-damaged keratinocytes, subclinical non-visible lesions, early and late lesions, and in some cases, invasive SCC.

 

Actinic Keratosis are dysplastic proliferations of keratinocytes with potential for malignant transformation. Clinically, Actinic Keratosis are warty growths appearing as macules, papules, or hyper-keratotic plaques with an erythematous background where its etiology involves both individual as well as environmental factors.

 

Actinic Keratosis are diagnosed clinically in the majority of the cases. The diagnosis is done by skin examination and confirmed by skin biopsy if needed. Other non-invasive imaging methods, such as confocal microscopy (CM), are useful in specific situations while doubtful cases of Actinic Keratosis require histo-pathological study to confirm the diagnosis.

 

Actinic Keratosis is not a fatal condition but it is important to understand its morbidity, particularly the effects on quality of life. However, prospective analyses found that as individuals developed new Actinic Keratosis over time, their skin-related quality of life did not change, suggesting that Actinic Keratosis count may be an indicator rather than a cause of worse skin related quality of life.

 

Actinic Keratosis has a multitude treatment algorithm. Topical treatments include, Imiquimod, Ingenol mebutate, and fluorouracil. Along with the medications prescribed, ablative-surgical treatments such as cryotherapy, scraping (curettage), and laser therapy are included as therapeutic treatment options for treating Actinic Keratosis patients.

 

Actinic Keratosis (AK) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Actinic Keratosis (AK) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Actinic Keratosis (AK) market report gives a thorough understanding of Actinic Keratosis symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Actinic Keratosis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Actinic Keratosis (AK) Epidemiology

The epidemiology division’s Actinic Keratosis (AK) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Actinic Keratosis (AK) epidemiology segmented as the Total Prevalent Cases of Actinic Keratosis (AK), Sub-type Specific Prevalent cases of Actinic Keratosis, Gender Specific Prevalence of Actinic Keratosis. The report includes the prevalent Actinic Keratosis scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Actinic Keratosis (AK) Epidemiology

The epidemiology segment also provides the Actinic Keratosis (AK) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 7MM prevalent cases of Actinic Keratosis (AK) were 18,524 in 2020.

Actinic Keratosis (AK) Drug Chapters

The drug chapter segment of the Actinic Keratosis (AK) report encloses the detailed analysis of Actinic Keratosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Actinic Keratosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Actinic Keratosis (AK) Emerging Drugs

 

VDA-1102: Vidac Pharma

In May 2018, Vidac Pharma initiated a Phase II, non-randomized, Phase IIb open-label study to evaluate the efficacy, safety, and tolerability of topical VDA-1102 ointment in subjects with Actinic Keratosis.

 

A Phase IIa005Av B was successfully completed in 2019 (NCT 03538951) demonstrating a 40% complete clearance and 80% lesions reduction in 50% of the population with a good skin permeability to the present formulation. A Phase II C with a slightly enhanced skin permeability is programmed as soon the Covid Pandemic allows.

Products detail in the report…

Actinic Keratosis (AK) Market Outlook

The Actinic Keratosis market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Actinic Keratosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of Actinic Keratosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, Actinic Keratosis (AK) market in 7MM is expected to change in the study period 2018–2030.

 

Key Findings

This section includes a glimpse of the Actinic Keratosis market in 7MM. The market size of Actinic Keratosis in the seven major markets was found to be USD 1,356.1 million in 2020.

 

The United States Market Outlook

This section provides a total of Actinic Keratosis market size and market size by therapies in the United States.

 

The United States accounts for the highest AK market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Actinic Keratosis (AK) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Actinic Keratosis (AK) market size and market size by therapies in Japan are also mentioned.

Actinic Keratosis (AK) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Actinic Keratosis (AK) market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Actinic Keratosis (AK) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Actinic Keratosis (AK) key players involved in developing targeted therapeutics.

 

Major players VDA-1102 (Vidac Pharma), DFD-07 (Promius Pharma), SR-T100 (G&E Herbal Biotechnology), GDC695 (Gage Development Company), and others are being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Actinic Keratosis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working on Actinic Keratosis domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Actinic Keratosis market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Actinic Keratosis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Actinic Keratosis (AK) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Actinic Keratosis (AK) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Actinic Keratosis provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Actinic Keratosis (AK) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Actinic Keratosis (AK) market

Report Highlights

  • In the coming years, Actinic Keratosis (AK) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Actinic Keratosis (AK) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Actinic Keratosis. The launch of emerging therapies will significantly impact the Actinic Keratosis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Actinic Keratosis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Actinic Keratosis (AK) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Actinic Keratosis (AK) Pipeline Analysis
  • Actinic Keratosis (AK) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Actinic Keratosis (AK) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Actinic Keratosis (AK) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Actinic Keratosis (AK) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Actinic Keratosis (AK) Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Actinic Keratosis (AK) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Actinic Keratosis (AK) market Size during the forecast period (2021–2030)?
  • At what CAGR, the Actinic Keratosis (AK) market is expected to grow by 7MM during the forecast period (2021–2030)?
  • What would be the Actinic Keratosis (AK) market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Actinic Keratosis (AK) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Actinic Keratosis (AK)?
  • What is the historical Actinic Keratosis (AK) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Actinic Keratosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Actinic Keratosis (AK)?
  • Out of all 7MM countries, which country would have the highest prevalent Actinic Keratosis (AK) population during the forecast period (2021–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Actinic Keratosis (AK)?
  • What are the current treatment guidelines for treating Actinic Keratosis (AK) in the USA, Europe, and Japan?
  • What are the Actinic Keratosis (AK) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Actinic Keratosis (AK)?
  • How many therapies are developed by each company for the treatment of Actinic Keratosis (AK)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Actinic Keratosis (AK)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Actinic Keratosis (AK) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Actinic Keratosis (AK) and their status?
  • What are the key designations that have been granted for the emerging therapies for Actinic Keratosis (AK)?
  • What are the global historical and forecasted markets of Actinic Keratosis (AK)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Actinic Keratosis (AK) market
  • To understand the future market competition in the Actinic Keratosis (AK) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis (AK) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis (AK) market
  • To understand the future market competition in the Actinic Keratosis (AK) market

1. Key Insights

2. Report Introduction

3. Actinic Keratosis Market Overview at a Glance

3.1. Market Share (%) Distribution Actinic Keratosis in 2018

3.2. Market Share (%) Distribution of Actinic Keratosis in 2030

4. Executive Summary of Actinic Keratosis

5. Organizations contributing towards Actinic Keratosis

6. Disease Background and Overview

6.1. Introduction

6.2. Signs and Symptoms

6.3. Classification Systems

6.4. Clinical variants of Actinic Keratosis

6.5. Pathogenesis

6.6. Pathophysiology

6.7. Genetic Basis of Actinic Keratosis

6.8. Causes and Risk factors for Actinic Keratosis

6.9. Diagnosis

7. Treatment and Management

7.1. Treatment goals

7.2. Lesion-Directed Therapies: First line treatment

7.3. Field-Directed Therapies: Topical therapies

7.4. Photodynamic therapy

7.5. British Association of Dermatologists Guidelines

7.6. American Academy of Dermatology

7.6.1. Guideline highlights

7.7. Evidence and consensus based (S3) Guidelines

7.8. Japanese Dermatological Association

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Total Prevalent Patient Population of Actinic Keratosis

8.3. Assumption and Rationale

8.4. The United States

8.4.1. Total Diagnosed Prevalent Cases of Actinic Keratosis in the United States

8.4.2. Prevalence of Actinic Keratosis based on Gender in the United States

8.4.3. Prevalence of Actinic Keratosis based on Age in the United States

8.5. EU5

8.5.1. Germany

8.5.1.1. Total Diagnosed Prevalent Cases of Actinic Keratosis in Germany

8.5.1.2. Prevalence of Actinic Keratosis based on Gender in Germany

8.5.1.3. Prevalence of Actinic Keratosis based on Age in Germany

8.5.2. France

8.5.2.1. Total Diagnosed Prevalent Cases of Actinic Keratosis in France

8.5.2.2. Prevalence of Actinic Keratosis based on Gender in France

8.5.2.3. Prevalence of Actinic Keratosis based on Age in France

8.5.3. Italy

8.5.3.1. Total Diagnosed Prevalent Cases of Actinic Keratosis in Italy

8.5.3.2. Prevalence of Actinic Keratosis based on Gender in Italy

8.5.3.3. Prevalence of Actinic Keratosis (AK) based on Age in Italy

8.5.4. Spain

8.5.4.1. Total Diagnosed Prevalent Cases of Actinic Keratosis in Spain

8.5.4.2. Prevalence of Actinic Keratosis based on Gender in Spain

8.5.4.3. Prevalence of Actinic Keratosis based on Age in Spain

8.5.5. United Kingdom

8.5.5.1. Total Diagnosed Prevalent Cases of Actinic Keratosis in United Kingdom

8.5.5.2. Prevalence of Actinic Keratosis based on Gender in United Kingdom

8.5.5.3. Prevalence of Actinic Keratosis based on Age in United Kingdom

8.6. Japan

8.6.1. Total Diagnosed Prevalent Cases of Actinic Keratosis in Japan

8.6.2. Prevalence of Actinic Keratosis based on Gender in Japan

8.6.3. Prevalence of Actinic Keratosis based on Age in Japan

9. Patient Journey

10. Case Report

11. Marketed Therapies

11.1. Klisyri (Tirbanibulin): Athenex/ Almirall

11.1.1. Drug Description

11.1.2. Regulatory Milestones

11.1.3. Other Development Activities

11.1.4. Clinical Development

11.1.5. Clinical Trials Information

11.1.6. Safety and efficacy

11.1.7. Product Profile

11.2. Imiquimod

11.2.1. Drug Description

11.2.2. Mechanism of action

11.3. Diclofenac Sodium

11.3.1 Drug Description

11.4. 5-Fluorouracil

11.4.1. Drug Description

11.4.2. Mechanism of action

12. Emerging Drugs

12.1. VDA-1102: Vidac Pharma

12.1.1. Drug Description

12.1.2. Other Developmental Activities

12.1.3. Clinical Development

12.1.4. Clinical Trials Information

12.1.5. Safety and efficacy

12.1.6. Product Profile

12.2. DFD-07: Promius Pharma

12.2.1. Drug Description

12.2.2. Clinical Development

12.2.3. Clinical Trials Information

12.2.4. Product Profile

To be continued in Report…

13. Other Therapies: Generics

13.1. Picato

13.1.1. Drug Description

13.1.2. Mechanism of action

13.2. 5-Aminolaevulinic Acid

13.2.1. Drug Description

13.2.2. Mechanism of Action

13.3. Tretinoin

13.3.1. Drug Description

13.3.2. Mechanism of action

13.4. Jessner’s Solution

13.4.1. Drug Description

13.4.2. Mechanism of action

14. Actinic Keratosis: 7 Major Market Analysis

14.1. Key Findings 

14.2. Market Size of Actinic Keratosis in 7 MM

14.3. Market Size of Actinic Keratosis by Therapies

15. Market Outlook

15.1. United States Market Size

15.1.1. Total Market Size of Actinic Keratosis in the United States

15.1.2. Market Size of Actinic Keratosis by Therapies in the United States

15.2. EU-5 Market Size

15.2.1. Germany

15.2.1.1. Total Market size of Actinic Keratosis in Germany

15.2.1.2. Market Size of Actinic Keratosis of Therapies in Germany

15.2.2. France

15.2.2.1. Total Market size of Actinic Keratosis in France

15.2.2.2. Market Size of Actinic Keratosis of Therapies in France

15.2.3. Italy

15.2.3.1. Total Market size of Actinic Keratosis in Italy

15.2.3.2. Market Size of Actinic Keratosis of Therapies in Italy

15.2.4. Spain

15.2.4.1. Total Market size of Actinic Keratosis in Spain

15.2.4.2. Market Size of Actinic Keratosis of Therapies in Spain

15.2.5. United Kingdom

15.2.5.1. Total Market size of Actinic Keratosis in United Kingdom

15.2.5.2. Market Size of Actinic Keratosis of Therapies in United Kingdom

15.3. Japan

15.3.1. Total Market size of Actinic Keratosis in Japan

15.3.2. Market Size of Actinic Keratosis by Therapies in Japan

16. KOL Views

17. Unmet Needs

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Appendix

21.1. Bibliography

21.2. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Table

Table 1: Summary of Actinic Keratosis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Organizations contributing towards Actinic Keratosis

Table 3: Clinical variants of Actinic Keratosis Criteria for Grading KIN

Table 4: Reclassification of Actinic Keratosis

Table 5: Clinical grading system (according to Olsen 1991)

Table 6: Risk factors for the development of basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs)

Table 7: Diagnostic Criteria for Actinic Keratosis

Table 8: European Medicines Agency Approval Status of Ranked Treatments for Actinic Keratosis

Table 9: Therapies recommended for Actinic Keratosis based on Severity

Table 10: British guidelines for treatment of Actinic Keratosis

Table 11: Key recommendations

Table 12: Overview of the recommendations for the treatment of Actinic Keratosis

Table 13: A practical report and treatment algorithm from Actinic Keratosis Team expert clinicians

Table 14: Japanese guidelines for treatment of Actinic Keratosis

Table 15: Prevalent Patient Population of Actinic Keratosis in 7 MM (2018–2030)

Table 16: Prevalent Cases of Actinic Keratosis in the United States (2018–2030)

Table 17: Prevalence of Actinic Keratosis based on Gender in the United States (2018–2030)

Table 18: Prevalence of Actinic Keratosis based on Age in the United States(2018–2030)

Table 19: Total Diagnosed Prevalent Cases of Actinic Keratosis in Germany(2018–2030)

Table 20: Prevalence of Actinic Keratosis based on Gender in Germany (2018–2030)

Table 21: Prevalence of Actinic Keratosis based on Age in Germany (2018–2030)

Table 22: Total Diagnosed Prevalent Cases of Actinic Keratosis in France (2018–2030)

Table 23: Prevalence of Actinic Keratosis based on Gender in France (2018–2030)

Table 24: Prevalence of Actinic Keratosis based on Age in France (2018–2030)

Table 25: Total Diagnosed Prevalent Cases of Actinic Keratosis in Italy (2018–2030)

Table 26: Gender specific Prevalence of Actinic Keratosis in Italy (2018–2030)

Table 27: Prevalence of Actinic Keratosis based on Age in Italy (2018–2030)

Table 28: Total Diagnosed Prevalent Cases of Actinic Keratosis in Spain (2018–2030)

Table 29: Prevalence of Actinic Keratosis based on Gender in Spain (2018–2030)

Table 30: Age specific Prevalence of Actinic Keratosis in Spain (2018–2030)

Table 31: Total Diagnosed Prevalent Cases of Actinic Keratosis in the UK (2018–2030)

Table 32: Gender specific Prevalence of Actinic Keratosis in the UK (2018–2030)

Table 33: Prevalence of Actinic Keratosis based on Age in the UK (2018–2030)

Table 34: Total Diagnosed Prevalent Cases of Actinic Keratosis in Japan (2018–2030)

Table 35: Prevalence of Actinic Keratosis based on Gender in Japan (2018–2030)

Table 36: Prevalence of Actinic Keratosis based on Age in Japan (2018–2030)

Table 37: KLISYRI, Clinical Trial Description, 2021

Table 38: VDA-1102, Clinical Trial Description, 2021

Table 39: DFD-07, Clinical Trial Description, 2021

Table 40: SR-T100, Clinical Trial Description, 2021

Table 41: GDC695, Clinical Trial Description, 2021

Table 42: PD P 506 A (Alas are), Clinical Trial Description, 2021

Table 43: AM-001, Clinical Trial Description, 2021

Table 44: Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 45: 7 Major Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Table 46: United States Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 47: Germany Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Table 48: Germany Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 49: Germany Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Table 50: France Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 51: France Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Table 52: Italy Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 53: Italy Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Table 54: Spain Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 55: Spain Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Table 56: United Kingdom Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 57: United Kingdom Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Table 58: Japan Market Size of Actinic Keratosis in USD Million (2018–2030)

Table 59: Japan Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Signs and Symptoms of Actinic Keratosis

Figure 2: Clinical variants of Actinic Keratosis

Figure 3: Mechanisms involved in Actinic Keratosis pathogenesis.

Figure 4: Causes of Actinic Keratosis

Figure 5: Proposed algorithm for treatment of Actinic Keratosis

Figure 6: Signs and Symptoms of Actinic Keratosis

Figure 7: Treatment Algorithm Based on Expert Consensus

Figure 8: Prevalent Patient Population of Actinic Keratosis in 7MM (2018–2030)

Figure 9: Total Diagnosed Prevalent Cases of Actinic Keratosis in the United States (2018–2030)

Figure 10: Prevalence of Actinic Keratosis based on Gender in the United States (2018–2030)

Figure 11: Prevalence of Actinic Keratosis based on Age in the United States (2018–2030)

Figure 12: Total Diagnosed Prevalent Cases of Actinic Keratosis in Germany (2018–2030)

Figure 13: Prevalence of Actinic Keratosis based on Gender in Germany (2018–2030)

Figure 14: Prevalence of Actinic Keratosis based on Age in Germany (2018–2030)

Figure 15: Total Diagnosed Prevalent Cases of Actinic Keratosis in France (2018–2030)

Figure 16: Prevalence of Actinic Keratosis based on Gender in France (2018–2030)

Figure 17: Prevalence of Actinic Keratosis based on Age in France (2018–2030)

Figure 18: Total Diagnosed Prevalent Cases of Actinic Keratosis in Italy (2018–2030)

Figure 19: Prevalence of Actinic Keratosis based on Gender in Italy (2018–2030)

Figure 20: Prevalence of Actinic Keratosis based on Age in Italy (2018–2030)

Figure 21: Total Diagnosed Prevalent Cases of Actinic Keratosis in Spain (2018–2030)

Figure 22: Prevalence of Actinic Keratosis based on Gender in Spain (2018–2030)

Figure 23: Prevalence of Actinic Keratosis based on Age in Spain (2018–2030)

Figure 24: Total Diagnosed Prevalent Cases of Actinic Keratosis in the UK (2018–2030)

Figure 25: Gender specific Prevalence of Actinic Keratosis in the UK (2018–2030)

Figure 26: Prevalence of Actinic Keratosis based on Age in the UK (2018–2030)

Figure 27: Total Diagnosed Prevalent Cases of Actinic Keratosis in Japan (2018–2030)

Figure 28: Prevalence of Actinic Keratosis based on Gender in Japan (2018–2030)

Figure 29: Prevalence of Actinic Keratosis based on Age in Japan (2018–2030)

Figure 30: 7 Major Market Size of Actinic Keratosis in USD Million (2018–2030)

Figure 31: 7 Major Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Figure 32: Total Market Size of Actinic Keratosis in the United States, USD Million (2018–2030)

Figure 33: The United States Size of Actinic Keratosis by Therapies by Class in USD Million (2018–2030)

Figure 34: Total Market Size of Actinic Keratosis in Germany, USD Million (2018–2030)

Figure 35: Germany Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Figure 36: Total Market Size of Actinic Keratosis in France, USD Million (2018–2030)

Figure 37: France Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Figure 38: Total Market Size of Actinic Keratosis in Italy, USD Million (2018–2030)

Figure 39: Italy Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Figure 40: Total Market Size of Actinic Keratosis in Spain, USD Million (2018–2030)

Figure 41: Spain Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Figure 42: Total Market Size of Actinic Keratosis in United Kingdom, USD Million (2018–2030)

Figure 43: United Kingdom Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Figure 44: Market Size of Actinic Keratosis in Japan, USD Million (2018–2030)

Figure 45: Japan Market Size of Actinic Keratosis by Therapies in USD Million (2018–2030)

Athenex
Almirall
Vidac Pharma
Promius Pharma

 

Forward to Friend

Need A Quote